We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.15%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$843M
AUM Growth
+$92.2M
Cap. Flow
+$126M
Cap. Flow %
14.96%
Top 10 Hldgs %
33.86%
Holding
109
New
20
Increased
44
Reduced
26
Closed
18

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$21.4M
2
CVS icon
CVS Health
CVS
+$19M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.7M
4
RVTY icon
Revvity
RVTY
+$16.1M
5
UNH icon
UnitedHealth
UNH
+$15.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$27.5M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$20.3M
3
ABT icon
Abbott
ABT
+$20M
4
GILD icon
Gilead Sciences
GILD
+$16.1M
5
BSX icon
Boston Scientific
BSX
+$11.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
26
Danaher
DHR
$145B
$13M 1.54%
+63,250
New +$13.8M
MNKD icon
27
MannKind Corp
MNKD
$1.24B
$12.5M 1.49%
2,493,836
-632,891
-20% -$3.55M
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.65B
$11M 1.31%
304,244
+204,085
+204% +$8.49M
DGX icon
29
Quest Diagnostics
DGX
$26.2B
$10.6M 1.26%
62,593
-27,759
-31% -$4.56M
AXGN icon
30
Axogen
AXGN
$2.67B
$9.93M 1.18%
536,832
+171,129
+47% +$3.09M
XERS icon
31
Xeris Biopharma Holdings
XERS
$1.55B
$9.77M 1.16%
1,780,454
+1,201,943
+208% +$4.85M
RCUS icon
32
Arcus Biosciences
RCUS
$3.69B
$9.54M 1.13%
1,215,629
-58,160
-5% -$674K
SDGR icon
33
Schrodinger
SDGR
$1.39B
$9.5M 1.13%
481,470
-81,621
-14% -$1.84M
EWTX icon
34
Edgewise Therapeutics
EWTX
$4.73B
$9.36M 1.11%
425,407
+44,234
+12% +$1.16M
REPL icon
35
Replimune Group
REPL
$1.28B
$9.27M 1.1%
950,399
+80,640
+9% +$998K
DXCM icon
36
DexCom
DXCM
$34.3B
$8.9M 1.06%
130,367
+51,817
+66% +$4.23M
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
$8.7M 1.03%
+753,752
New +$7.69M
DAWN
38
DELISTED
Day One Biopharmaceuticals
DAWN
$8.27M 0.98%
1,043,162
+42,688
+4% +$460K
NUVL
39
DELISTED
Nuvalent
NUVL
$7.8M 0.93%
109,988
+86,400
+366% +$6.76M
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.71B
$7.5M 0.89%
1,000,562
+783,681
+361% +$6.32M
SNDX icon
41
Syndax Pharmaceuticals
SNDX
$1.77B
$7.31M 0.87%
594,987
+68,014
+13% +$959K
ANIP icon
42
ANI Pharmaceuticals
ANIP
$1.73B
$7.03M 0.83%
+105,000
New +$6.27M
CSTL icon
43
Castle Biosciences
CSTL
$960M
$7.02M 0.83%
350,551
+45,922
+15% +$1.14M
LIVN icon
44
LivaNova
LIVN
$4.45B
$6.55M 0.78%
166,871
-8,063
-5% -$362K
QDEL icon
45
QuidelOrtho
QDEL
$1.02B
$6.42M 0.76%
183,678
+8,263
+5% +$337K
TMCI icon
46
Treace Medical Concepts
TMCI
$309M
$5.99M 0.71%
+713,539
New +$6.41M
XENE icon
47
Xenon Pharmaceuticals
XENE
$6.31B
$5.86M 0.69%
174,576
-18,428
-10% -$700K
DOCS icon
48
Doximity
DOCS
$4.45B
$5.43M 0.64%
+93,500
New +$5.9M
RMD icon
49
ResMed
RMD
$32.8B
$5.06M 0.6%
+22,622
New +$5.28M
VCYT icon
50
Veracyte
VCYT
$3.59B
$4.93M 0.58%
166,278
+65,977
+66% +$2.51M
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Parkman Healthcare Partners held 109 positions worth $843M, up 12% from $751M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Parkman Healthcare Partners deployed $126M of net new capital in Q1 2025, opening 20 new positions and adding to 44 existing holdings. Its largest new stake was Zimmer Biomet: 200,500 shares worth $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $27.5M trimmed.

  • Parkman Healthcare Partners's largest Q1 2025 buy was Zimmer Biomet: 200,500 shares worth $22.7M.
  • Parkman Healthcare Partners added most to CVS Health in Q1 2025, an estimated $19M increase.
  • Parkman Healthcare Partners's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $27.5M.
  • Parkman Healthcare Partners fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $20.3M.
  • Parkman Healthcare Partners's ten largest holdings make up 34% of its $843M portfolio in Q1 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 18 in Q1 2025.
  • Parkman Healthcare Partners's portfolio value rose 12% quarter-over-quarter to $843M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.